NYSEMKT: PLXProtalix Biotherapeutics Inc Stock
$1.49-0.05 (-3.25%)
Updated Jun 13, 2025
PLX Price
$1.49
Fair Value Price
N/A
Market Cap
$118.61M
52 Week Low
$0.82
52 Week High
$3.10
P/E
29.8x
P/B
2.62x
P/S
3.28x
PEG
N/A
Dividend Yield
N/A
Revenue
$59.76M
Earnings
$3.91M
Gross Margin
50%
Operating Margin
9.76%
Profit Margin
6.5%
Debt to Equity
0.63
Operating Cash Flow
-$572k
Beta
0.62
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PLX Overview
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; OPRX-106, an orally-delivered protein product candidate for the treatment of inflammatory bowel disease, as well as completed Phase IIa clinical trial for ulcerative colitis patients; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; and PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is headquartered in Karmiel, Israel.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PLX's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PLX
Ranked#21 of 464
Ranked#21 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.18 | A | |
| $41.59 | A | |
| $23.53 | A |
Be the first to know about important PLX news, forecast changes, insider trades & much more!
PLX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PLX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PLX was unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PLX is good value based on its earnings relative to its share price (29.8x), compared to the US market average (31.36x)
P/E vs Market Valuation
PLX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more PLX due diligence checks available for Premium users.
Valuation
PLX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
29.8x
Industry
-108.97x
Market
31.36x
PLX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
PLX is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
PLX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.62x
Industry
4.66x
PLX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PLX's financial health
Profit margin
Revenue
$10.1M
Net Income
-$3.6M
Profit Margin
-35.8%
PLX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
PLX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$73.9M
Liabilities
$28.7M
Debt to equity
0.63
PLX's short-term assets ($60.51M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PLX's short-term assets ($60.51M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PLX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PLX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.1M
Investing
-$312.0k
Financing
$5.1M
PLX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PLX vs Biotech Stocks
Protalix Biotherapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.